Brind.

Rexall derives a substantial share of its revenues from the U.S. Pharmaceutical segment, fueled by GLP-1 demand and specialty pharma sales.

1 report, 1 independent Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Rexall derives a substantial share of its revenues from the U.S. Pharmaceutical segment, fueled by GLP-1 demand and specialty pharma sales.

Who's involved

What this event is mainly about
Rexall

Keep exploring

The entities involved

  • Rexall

    Chain of drugstores

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • ZacksWill GLP-1 Demand Drive MCK's Top Line This Earnings Season? McKesson Corporation MCK is scheduled to report first-quarter fiscal 2026 results on Aug. 6, after market close. The company delivered an